title: Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy.
abstract: OBJECTIVE
  To investigate whether body mass index (BMI) is a prognostic factor for biochemical recurrence (BCR) in Dutch men after radical prostatectomy (RP), as although epidemiological studies of obesity in relation to prostate cancer have provided conflicting results, recent studies from the USA suggest that a higher BMI is a risk factor for progression of prostate cancer.
  
  
  METHODS
  Of the 1417 patients with prostate cancer who had RP at two University hospitals, 1302 were included in the present study. BMI (kg/m(2)) classes were defined as normal (<25), overweight (25-30) and obese (> or =30). The median follow-up was 59 months and clinical data were obtained retrospectively from charts. BCR was defined as two consecutive prostate-specific antigen (PSA) levels of >0.1 ng/mL.
  
  
  RESULTS
  In all, 600 patients were classified as having normal weight (43.9%), 665 as overweight (48.6%) and 103 as obese (7.5%). Overall, 297 patients developed BCR after RP; the 10-year risk (95% confidence interval) of BCR was 31.9 (26.6-37.2)%, 30.5 (25.8-35.2)% and 23.9 (14.9-32.9)% for patients in the three categories, respectively (P = 0.836). Multivariable proportional hazard regression analyses of BMI and established prognostic factors for BCR did not change these results.
  
  
  CONCLUSIONS
  BMI appeared to have no prognostic value for BCR in Dutch patients with clinically localized prostate cancer and treated with RP.
authors.affiliation: Department of Urology, University Medical Center Utrecht, The Netherlands.
authors.forename: Joep G H
authors.initials: JG
authors.lastname: van Roermund
authors.forename: Dieuwertje E G
authors.initials: DE
authors.lastname: Kok
authors.forename: Mark F
authors.initials: MF
authors.lastname: Wildhagen
authors.forename: Lambertus A
authors.initials: LA
authors.lastname: Kiemeney
authors.forename: Femke
authors.initials: F
authors.lastname: Struik
authors.forename: Sarah
authors.initials: S
authors.lastname: Sloot
authors.forename: Inge M
authors.initials: IM
authors.lastname: van Oort
authors.forename: Christina A
authors.initials: CA
authors.lastname: Hulsbergen-van de Kaa
authors.forename: Geert J L H
authors.initials: GJ
authors.lastname: van Leenders
authors.forename: Chris H
authors.initials: CH
authors.lastname: Bangma
authors.forename: J Alfred
authors.initials: JA
authors.lastname: Witjes
mesh_terms: D000368:Aged; D015992:Body Mass Index; D004812:Epidemiologic Methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis*; D009765:Obesity / Q000150:complications; D050177:Overweight / Q000150:complications; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000097:blood / Q000150:complications / Q000473:pathology* / Q000601:surgery
chemical_list: D017430:Prostate-Specific Antigen